DESOMEDINE

Bacterial infections of the eye and its annexes with sensitive germs such as conjunctivitis, keratoconjunctivitis, blepharites, dacrycystitis.

Special warnings Risk of allergy

Avoid long-term or frequent treatment due to the risk of resistant strains.

Hexamidine, like any cationic, is incompatible with anionics.

The use of contact lenses is contraindicated throughout the duration of treatment Paediatric population DESOMEDINE 0.1%, eye drops in solution should not be considered as a prophylactic treatment of the conjunctiva in the newborn.

Considering the presence of borax and boric acid, this medication should not be given to a child under 2 years of age at a dose greater than 5 drops/oeil/day, as it may affect its future fertility.

Pharmacotherapeutic group

Antiseptic, ATC code: S01AX08 Hexamidine (a member of the diamidone family) is an antibacterial cationic agent with surfactant properties.

In vitro, its activity is exercised on Gram+ bacteria and is not inhibited by pus, serum and organic debris, as well as on both forms (trophozoites and cysts) of the Acanthamoeba-like amoeba.

DESOMEDINE is a nonpreservative eyelide, in solution in a multidose container.

Paediatric population

A wide spectrum of pathogenic organisms is associated with bacterial conjunctivitis in adults and children.

Existing literature shows that, as in adults, the pathogens most frequently associated with bacterial conjunctivitis in children are Gram-positive bacteria (i.e., Staphylococci and Streptococci spp).

Hexamidine may cause hypersensitivity reactions.

• List of Adverse Reactions: Adverse events are classified according to the following frequency categories: very common (≥ 1/10); common (≥ 1/100, < 1/10); uncommon (≥ 1/1,000, < 1/100); rare (≥ 1/1,000, < 1/1,000); very rare (< 1/10,000); unknown frequency (cannot be estimated from available data).

Immune system disorders

Not known (cannot be estimated from available data): hypersensitivity reactions (irritation or awareness) Reporting suspected adverse reactions Reporting suspected adverse reactions following drug authorization is important and allows for ongoing monitoring of the benefit/risk ratio of the drug.

Health care professionals report suspected adverse reactions via the national reporting system: National Drug and Health Products Safety Agency (NSSA) and the Network of Pharmacovigilance Regional Centres.